There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

Like recombinant DNA before it, gene editing has the potential to transform medicine, agriculture and more. CRISPR is now used by thousands of biologists in labs across the globe. A revolution in food ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.